SARASOTA, FL - Silo Pharma Inc. (NASDAQ:SILO), a biopharmaceutical company, has announced positive developments in its pre-clinical research for SP-26, a time-released ketamine formulation aimed at treating fibromyalgia and chronic pain. The company reported that recent tests have successfully demonstrated the structural stability of the drug-loaded polymer implants, which are designed to provide controlled, sustained release of medication.
The study involved analytical testing and small batch extrusion trials to assess drug release and stability. According to the company's CEO, Eric Weisblum, the 20% and 40% ketamine hydrochloride-loaded implants showed no signs of leakage, degradation, or discoloration, indicating that the implants maintained their integrity. Weisblum highlighted the potential of implantable drug delivery systems (IDDS) like SP-26 to offer continuous relief from chronic pain, contrasting with the fluctuating concentrations of medication in the bloodstream resulting from conventional oral or injectable drugs.
SP-26 is a ketamine-based dissolvable subcutaneous implant that is being developed to regulate dosage and time release safely. If successful in clinical trials, SP-26 could be eligible for the FDA's 505(b)(2) regulatory pathway, which could streamline the drug approval process.
Silo Pharma specializes in developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. The company's portfolio includes a lead program, SPC-15, targeting PTSD and stress-induced anxiety disorders, and preclinical programs such as SPC-14 for Alzheimer’s disease and SPU-16 for multiple sclerosis.
The company's research and development efforts are conducted in collaboration with Columbia University and the University of Maryland, Baltimore. This press release statement serves as the source of information for this report, and it contains forward-looking statements that involve risks and uncertainties. Silo Pharma cautions that these statements are predictions and actual events or results may differ.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.